Merck Serono, MVV to develop potential antimalarial therapy
DDD107498 was developed as part of a collaboration between MMV and the University of Dundee Drug Discovery Unit, led by Prof Ian Gilbert and Dr Kevin Read. The
Johnson & Johnson (J&J) has agreed to purchase Firefly Bio for $1bn in cash, aiming to strengthen its oncology pipeline with Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) platform.
Propafenone is indicated to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Additionally, it is indicated